Eli Lilly Covid-19 Antibody Treatment Trial Is Paused Due To ‘Potential Safety Concern’

Eli Lilly on Tuesday confirmed to the New York Times that a clinical trial for its antibody treatment for Covid-19 has been paused because of a “potential safety concern,” just one day after Johnson & Johnson halted its Covid-19 vaccine trial because a participant got sick.

An independent data safety monitoring board recommended a pause in enrolling new people in the trial. When researchers test promising treatments, sometimes unexpected side effects occur where the trial needs to be paused.